efficacy

Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
CAR T-cell therapy for neuroblastoma 2:24
CAR T-cell therapy for neuroblastoma
Shigeki Yagyu • 8 Apr 2022
Engineering NK cell-based cancer treatments 1:22
Engineering NK cell-based cancer treatments
Juliane Mietz • 1 Apr 2022
Overexpression of the LBTR gene to optimize T cell proliferation 1:54
Overexpression of the LBTR gene to optimize T cell proliferation
Mateusz Legut • 31 Mar 2022
Treating Krabbe disease with FBX-101 1:58
Treating Krabbe disease with FBX-101
John Maslowski • 27 Jan 2022
MOMENTUM: ARU-1801 in sickle cell disease 1:57
MOMENTUM: ARU-1801 in sickle cell disease
Will Chou • 26 Jan 2022
Applications of single-cell multi-omics analysis 7:04
Applications of single-cell multi-omics analysis
Yan Zhang • 21 Oct 2021
Utilizing single-cell multi-omics throughout the product pipeline 1:50
Utilizing single-cell multi-omics throughout the product pipeline
Yan Zhang • 21 Nov 2021
Challenges in developing cardiovascular advanced therapies 2:49
Challenges in developing cardiovascular advanced therapies
Monica Shah • 19 Oct 2021
Challenges in targeting the eye with cell therapy 2:12
Challenges in targeting the eye with cell therapy
Marie Csete • 20 Oct 2021
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
Advantages of allogeneic NK cell therapy 2:26
Advantages of allogeneic NK cell therapy
Kanya Rajangam • 13 Oct 2021
Developments in NK cell therapy 2:48
Developments in NK cell therapy
Kanya Rajangam • 13 Oct 2021
Treating hematologic malignancies with immunotherapy 0:59
Treating hematologic malignancies with immunotherapy
Kanya Rajangam • 13 Oct 2021
NKX019 in B-cell malignancies 1:05
NKX019 in B-cell malignancies
Kanya Rajangam • 13 Oct 2021
The content of VJRegenMed is intended for healthcare professionals